info:eu-repo/semantics/article
Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies
Fecha
2018-10-30Registro en:
Theoduloz, Cristina; Alzate-Morales, Jans; Jiménez Aspee, Felipe; Isla, Maria Ines; Alberto, Maria Rosa; et al.; Inhibition of key enzymes in the inflammatory pathway by hybrid molecules of terpenes and synthetic drugs: In vitro and in silico studies; Wiley Blackwell Publishing, Inc; Chemical Biology & Drug Design; 93; 3; 30-10-2018; 290-299
1747-0277
CONICET Digital
CONICET
Autor
Theoduloz, Cristina
Alzate-Morales, Jans
Jiménez Aspee, Felipe
Isla, Maria Ines
Alberto, Maria Rosa
Pertino, Mariano Walter
Schmeda Hirschmann, Guillermo
Resumen
The aim of this work was to compare the anti-inflammatory activity of compounds prepared from terpenes and the synthetic drugs ibuprofen and naproxen. The anti-inflammatory activity of the hybrid compounds was compared with the activity of the parent compounds. This was accomplished using in vitro inhibition of lipoxygenases (LOX) and COX-2, and in silico docking studies in 15-LOX and COX-2. The synthesized hybrids showed an inhibition of COX-2 and LOX between 9.8%–57.4% and 0.0%–97.7%, respectively. None of the hybrids showed an improvement in the inhibitory effect toward these pro-inflammatory enzymes, compared to the parent terpenes and non-steroidal anti-inflammatory drugs. The docking studies allowed us to predict the potential binding modes of hybrids 6–15 within COX-2 and 15-LOX active sites. The relative affinity of the compounds inside the binding sites could be explained by forming non-covalent interactions with most important and known amino acids reported for those enzymes. A good correlation (r 2 = 0.745) between docking energies and inhibition percentages against COX-2 was found. The high inhibition obtained for compound 10 against COX-2 was explained by hydrogen bond interactions at the enzyme binding site. New synthetic possibilities could be obtained from our in silico models, improving the potency of these hybrid compounds.